Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telzox
- Development stage
- Unknown
- Lead developer
- Lloyd Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telzox is a generic formulation of telmisartan, a small molecule angiotensin II receptor blocker (ARB) developed and marketed by Lloyd Healthcare. It is primarily indicated for the management of hypertension (high blood pressure) and to reduce the risk of cardiovascular events such as myocardial infarction and stroke. Additionally, it is used in the management of diabetic nephropathy in patients with type 2 diabetes. Telzox works by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, leading to vasodilation and reduced aldosterone secretion.
- Brand names
- Telzox
- Other names
- telmisartan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Telzox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telzox.